276 related articles for article (PubMed ID: 31229164)
21. New therapies in non-Hodgkin lymphoma.
Novelli S; Sierra J; Briones J
Expert Rev Anticancer Ther; 2015 Mar; 15(3):349-59. PubMed ID: 25582186
[TBL] [Abstract][Full Text] [Related]
22. The potential for immunoconjugates in lymphoma therapy.
Liu SY; Press OW
Hematol Oncol Clin North Am; 1997 Oct; 11(5):987-1006. PubMed ID: 9336727
[TBL] [Abstract][Full Text] [Related]
23. Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
Hu B; Jacobs R; Ghosh N
Curr Hematol Malig Rep; 2018 Dec; 13(6):543-554. PubMed ID: 30338457
[TBL] [Abstract][Full Text] [Related]
24. [Recent advances in pediatric non-Hodgkin lymphoma. Report on a retrospective single-center cohort and review of the literature].
Szegedi I; Gáspár I; Gyurina K; Zele Z; Kiss C
Magy Onkol; 2018 Dec; 62(4):204-213. PubMed ID: 30540862
[TBL] [Abstract][Full Text] [Related]
25. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
Abramson JS; Ghosh N; Smith SM
Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
Barth MJ; Chu Y; Hanley PJ; Cairo MS
Br J Haematol; 2016 May; 173(4):597-616. PubMed ID: 27062282
[TBL] [Abstract][Full Text] [Related]
27. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.
Chao MP; Alizadeh AA; Tang C; Myklebust JH; Varghese B; Gill S; Jan M; Cha AC; Chan CK; Tan BT; Park CY; Zhao F; Kohrt HE; Malumbres R; Briones J; Gascoyne RD; Lossos IS; Levy R; Weissman IL; Majeti R
Cell; 2010 Sep; 142(5):699-713. PubMed ID: 20813259
[TBL] [Abstract][Full Text] [Related]
28. Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma.
Chu Y; Gardenswartz A; Diorio C; Marks LJ; Lowe E; Teachey DT; Cairo MS
Best Pract Res Clin Haematol; 2023 Mar; 36(1):101442. PubMed ID: 36907635
[TBL] [Abstract][Full Text] [Related]
29. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
[TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab for the treatment of diffuse large B-cell lymphoma.
Sheikh S; Kuruvilla J
Expert Opin Biol Ther; 2019 Nov; 19(11):1119-1126. PubMed ID: 31456438
[No Abstract] [Full Text] [Related]
31. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies.
Tun AM; Ansell SM
Cancer Treat Rev; 2020 Aug; 88():102042. PubMed ID: 32521386
[TBL] [Abstract][Full Text] [Related]
32. Treatment of follicular non-Hodgkin's lymphoma.
Maloney DG
Curr Hematol Rep; 2005 Jan; 4(1):39-45. PubMed ID: 15610658
[TBL] [Abstract][Full Text] [Related]
33. Rituximab therapy for indolent non-Hodgkin's lymphoma.
Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586
[TBL] [Abstract][Full Text] [Related]
34. Emerging immunotherapy in pediatric lymphoma.
Erker C; Harker-Murray P; Burke MJ
Future Oncol; 2016 Jan; 12(2):257-70. PubMed ID: 26616565
[TBL] [Abstract][Full Text] [Related]
35. A review of monoclonal antibody therapies in lymphoma.
Teo EC; Chew Y; Phipps C
Crit Rev Oncol Hematol; 2016 Jan; 97():72-84. PubMed ID: 26318093
[TBL] [Abstract][Full Text] [Related]
36. [Not Available].
Bounaix L; Bendouda M; Bay JO; Lemal R
Bull Cancer; 2016 Nov; 103 Suppl 1():S160-S163. PubMed ID: 28057180
[TBL] [Abstract][Full Text] [Related]
37. GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas.
Schuster SJ; Venugopal P; Kern JC; McLaughlin P
Leuk Lymphoma; 2008 Sep; 49(9):1681-92. PubMed ID: 18798103
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
Fanale MA; Younes A
Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
[TBL] [Abstract][Full Text] [Related]
39. Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.
Chang A; Schlafer D; Flowers CR; Allen PB
Expert Opin Investig Drugs; 2018 Jan; 27(1):55-70. PubMed ID: 29228840
[TBL] [Abstract][Full Text] [Related]
40. New treatment approaches to indolent non-Hodgkin's lymphoma.
Seymour JF
Semin Oncol; 2004 Feb; 31(1 Suppl 2):27-32. PubMed ID: 15042532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
